F-1/A: Innocan Pharma Files F-1/A for NYSE American IPO

Innocan Pharma Corporation is seeking to raise approximately $10.89 million in an initial public offering on the NYSE American to advance its preclinical LPT-CBD drug delivery platform and expand its consumer wellness segment.

Summary

• Innocan Pharma Corporation is a pharmaceutical tech company operating in two segments: Pharmaceuticals and Consumer Wellness.
• The company is offering 2,350,000 units, each consisting of one common share and one warrant to purchase one common share, with an anticipated IPO price between $5.00 and $6.00 per unit.
• The warrants will have an exercise price of $6.875 per common share and expire five years from issuance.
• Net proceeds from the offering are estimated at approximately $10.89 million, or $12.67 million if the over-allotment option is fully exercised.
• Approximately $6.5 million of the net proceeds will be allocated to human applications R&D for the LPT-CBD project, and $2.5 million for veterinary applications R&D.
• The LPT-CBD platform is in late preclinical development, with a pre-IND meeting successfully completed with the FDA, structuring the development plan towards an IND submission.
• The company intends to submit an IND application for its initial Phase 1a study following LPT-CBD scale-up activities, expected to commence approximately three months post-offering and take about one year.
• A 65-for-1 reverse share split was effected on September 5, 2025, retroactively restating all share and per-share data.
• The company reported revenues of $29,437,000 for the year ended December 31, 2024, up from $13,657,000 in 2023, primarily driven by its B.I. Sky Global Ltd. subsidiary.
• Net loss for the year ended December 31, 2024, decreased to $262,000 from $4,248,000 in 2023.
• However, for the nine months ended September 30, 2025, net loss increased to $2,196,000 compared to $214,000 for the same period in 2024, attributed to decreased revenues and increased financial expenses.
• As of September 30, 2025, the company had an accumulated deficit of $38,027,000 and cash and cash equivalents of $7,270,000.
• The financial statements contain an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
• The company is an emerging growth company and a foreign private issuer, allowing for reduced reporting requirements and adherence to certain home country corporate governance practices.

Sentiment

Score: 5

Explanation: The company presents a mixed financial picture with continued losses and a going concern warning, indicating significant financial challenges. However, the ongoing IPO, promising preclinical data for LPT-CBD, and strategic regulatory pathways (505(b)(2), INAD) offer substantial future potential. The revenue growth in the Consumer Wellness segment in 2024 is positive, but the recent decline in Q3 2025 and increased net loss are concerning. The overall sentiment is neutral-to-slightly-positive, reflecting the high-risk, high-reward nature of a preclinical biotech company undergoing an IPO.

Positives

• The proprietary LPT-CBD injectable drug product has shown promise in preclinical research for both human and animal use, offering sustained release of synthetic cannabidiol with significant bioavailability as a non-opioid alternative for pain management.
• A robust intellectual property portfolio includes 31 published patents granted and pending across eight families, enhancing competitive position.
• An experienced, mission-driven team with business and scientific expertise is committed to addressing chronic pain conditions.
• The company is pursuing FDA 505(b)(2) accelerated regulatory pathways for LPT-CBD, which could streamline the drug development process by utilizing existing data from approved products like Epidiolex.
• The global pain management market is projected to grow to $109 billion by 2032 (CAGR 4.5%), and the veterinary pain management market to $2.20 billion by 2029 (CAGR 5.91%), indicating substantial market opportunities.
• The Consumer Wellness segment, particularly B.I. Sky Global Ltd., demonstrated strong revenue growth in 2024, with $29,399,000 from online sales, and boasts a low 0.01% return rate and 87.4% customer retention within 30 days.
• Preclinical studies in various animal models (mice, dogs, minipigs, goats) have demonstrated long-term analgesic effects, prolonged CBD plasma concentrations, and favorable tolerability for LPT-CBD.
• The FDA's Center for Veterinary Medicine (CVM) granted a sponsor fee waiver and an INAD number for LPT-CBD, facilitating its development as a new veterinary drug.

Negatives

• The company is a preclinical stage company in its Pharmaceuticals segment and has never generated revenue from LPT-CBD product sales, anticipating significant losses until commercialization.
• A history of net losses, with an accumulated deficit of $38,027,000 as of September 30, 2025, raises substantial doubt about the company's ability to continue as a going concern.
• The company expects to need additional funding, which may not be available on acceptable terms, or at all, potentially requiring curtailment, delay, or discontinuation of operations.
• Net loss increased to $2,196,000 for the nine months ended September 30, 2025, compared to $214,000 for the same period in 2024, primarily due to decreased revenues and increased financial expenses.
• Revenues decreased by $2,412,000 (10%) for the nine months ended September 30, 2025, compared to the same period in 2024, attributed to challenging market conditions and global trade tariffs.
• The 505(b)(2) accelerated pathway does not guarantee marketing approval, and if the FDA determines it's not applicable, additional non-clinical studies would be required, increasing time, cost, and risk.
• The company's reliance on third parties for clinical trials, research, preclinical testing, and manufacturing introduces risks of unsatisfactory performance, delays, or increased costs.
• As a foreign private issuer, the company follows certain home country corporate governance practices that may provide less protection to investors than those applicable to U.S. domestic issuers, such as not having a majority of independent directors or fully independent nominating/compensation committees.

Risks

• The company is a pre-clinical stage company and anticipates significant losses until commercialization of pharmaceutical products.
• May not achieve or maintain sufficient working capital to meet future obligations.
• Expects to need additional funding, which may not be available on acceptable terms, or at all, potentially requiring curtailment, delay, or discontinuation of operations.
• Financial statements contain an explanatory paragraph regarding substantial doubt about the ability to continue as a going concern.
• Pharmaceutical product candidates are in preclinical development, and there is no assurance any will receive regulatory approval.
• May not receive, or may be delayed in receiving, necessary approvals for LPT-CBD or future products.
• If the FDA's Section 505(b)(2) pathway is not available, drug development will likely take significantly longer, cost more, and entail greater complexity and risk.
• Legislative or regulatory reforms in the U.S. or EU may make it more difficult and costly to obtain regulatory clearances or approvals, or to manufacture, market, or distribute products.
• Clinical and preclinical development is uncertain; current preclinical programs may experience delays or never advance to clinical trials.
• Future clinical trials may be delayed, certain programs may never advance, or may be more costly.
• Clinical trials may fail to show safety and effectiveness, preventing regulatory approval and commercialization.
• Early-stage clinical trial results may not predict future results; initial data may not reflect final or later-stage trial outcomes.
• Research and development of central nervous system (CNS)-targeting drugs is difficult, making it hard to predict drug efficacy.
• Difficulties enrolling patients in clinical trials could delay or adversely affect clinical development.
• Product candidates may have side effects or safety risks, delaying or halting development, preventing approval, or limiting commercial potential.
• Approved products may fail to achieve market acceptance, affecting revenue and profitability.
• Clinical trials conducted outside the U.S. may not be accepted by FDA, EMA, or other regulatory authorities.
• Failure to obtain regulatory approval in any jurisdiction could substantially harm the business.
• Complex pharmaceutical product candidates may face manufacturing problems, delaying development or commercialization.
• May not use expedited development or regulatory review processes for breakthrough or fast track designated products.
• Approved products will face ongoing regulatory obligations and review, incurring additional expenses and potential penalties for non-compliance.
• If market opportunities for pharmaceutical product candidates are smaller than believed, revenue may be adversely affected.
• Commercial success of future pharmaceutical products depends on market acceptance by physicians, healthcare payers, patients, and the medical community.
• Inability to establish sales and marketing capabilities or enter agreements with third parties to sell and market product candidates may prevent successful commercialization.
• Faces intense competition and rapid technological change; competitors may develop similar, more advanced, or more effective therapies.
• Third-party payor coverage and reimbursement status of newly approved products is uncertain; failure to obtain or maintain coverage and adequate reimbursement could limit marketability.
• Failure to comply with controlled substance legislation could restrict or harm ability to develop and commercialize products.
• Cannabis remains illegal under U.S. federal law, and changes in enforcement priorities could render operations unprofitable or prohibit them.
• The cannabis industry and regulations continue to develop, and adverse changes may impact business and operations.
• Failure to comply with various regulations could prevent carrying on business and incur costs.
• May become involved in disputes and legal or regulatory proceedings that could materially affect business, financial condition, and results of operations.
• May be required to recall products and face product liability claims, resulting in unexpected costs and damaging reputation.
• If products are not manufactured in compliance with regulations, do not meet quality standards, or result in adverse health effects, it could cause reputational harm, remedial costs, or regulatory enforcement.
• New laws, regulations, enforcement trends, or changes in regulations governing the introduction, marketing, and sale of products could harm business.
• Facilities and those of third-party manufacturers are subject to regulation under the Federal Food, Drug, and Cosmetic Act (FDCA) and FDA regulations.
• Government regulations and private party actions relating to marketing may restrict ability to sell products and harm business.
• Government regulation of the Internet and e-commerce is evolving, and unfavorable changes or failure to comply could substantially harm business.
• Healthcare legislation aimed at reducing costs may have a material adverse effect on business.
• Governments outside the United States may impose strict price controls, adversely affecting revenues.
• May seek additional collaborations and may not be successful in maintaining or entering new ones, or may not realize benefits.
• Relies on third parties for clinical trials, research, and preclinical testing, who may not perform satisfactorily.
• Has no sales, distribution, or marketing experience and may invest significant resources to establish these capabilities; failure to do so may prevent revenue generation.
• Inability to obtain and maintain effective intellectual property rights may prevent effective competition.
• May be involved in lawsuits to protect or enforce intellectual property, which could be expensive, time-consuming, and unsuccessful.
• Needs to expand organization and may have difficulties managing growth, disrupting operations.
• May not succeed in identifying, discovering, or licensing additional product candidates.
• Employment laws may prevent enforcement of non-compete covenants, allowing competitors to benefit from former employees' expertise.
• Success depends on retaining executive officers and attracting, retaining, and motivating qualified personnel.
• Increasing scrutiny of sustainability and ESG initiatives could increase costs or adversely impact business.
• Unfavorable economic and market conditions and financial institution developments may adversely affect business, operating results, and growth rates.
• May be classified as a passive foreign investment company (PFIC), causing adverse tax consequences for U.S. shareholders.
• As a foreign private issuer, follows home country corporate governance practices and is not subject to certain U.S. securities laws and governance requirements.
• Recent initial public offerings of similar companies have experienced extreme volatility unrelated to performance, potentially affecting the assessment of share value.
• Part of operations are conducted in Israel; conditions in Israel, including armed conflicts, could materially and adversely affect business.
• Operations may be disrupted by the obligation of management or key personnel to perform military service.
• It may be difficult to enforce a U.S. judgment against the company, its officers, and directors not in the U.S., or to assert U.S. securities laws claims or serve process on them.
• Governed by Canadian corporate laws, which in some cases have a different effect on shareholders than U.S. corporate laws.
• Business and operations might be adversely affected by security breaches, including cybersecurity incidents.
• Sales or significant short sales of common shares, or the perception of such sales, could depress the market price and impair ability to raise capital.
• If securities or industry analysts do not publish or cease publishing research or reports, or publish negative reports, share price and trading volume could decline.

Future Outlook

The company plans to use IPO proceeds to fund research and development for human and veterinary applications of its LPT-CBD project, aiming for IND submission for Phase 1a human studies and INAD application for veterinary testing. It also intends to expand marketing and sales efforts for its consumer wellness products in the United States and explore new technologies and acquisitions. The company believes existing capital and IPO proceeds will fund operations for at least 12 months, but acknowledges that actual expenses could vary significantly.

Management Comments

• "We are committed to improving quality of life by addressing chronic pain in humans and animals through innovative therapeutic solutions."
• "We believe that progressing along a defined regulatory support and pathways will position us well in the market and on track to commercialization."
• "Our objective is to positively impact lives by addressing chronic pain in humans and animals, as well as promote wellness through innovative products."
• "We stand at the forefront of addressing some of the most pressing health challenges today through our innovative use of sustained-release liposomal technology."
• "Our work is not just about creating breakthrough products but about answering a call to action highlighted by the opioid crisis."
• "We are committed to bringing safer, effective alternatives to the market, transforming the landscape of chronic pain management and wellness."

Industry Context

The company operates within the substantial global pain management market, projected to reach $109 billion by 2032, driven by rising chronic diseases and the urgent need for non-opioid alternatives due to the opioid crisis. The veterinary pain management market is also growing, estimated to reach over $2.20 billion by 2029, fueled by increased pet ownership and health awareness. The beauty and personal care market, where Innocan's Consumer Wellness segment competes, is projected to reach $693 billion by 2031, with significant growth in online sales. Innocan aims to differentiate itself by offering non-addictive, high-bioavailability, and low-side-effect CBD-based solutions, aligning with the FDA's support for non-opioid pain treatments.

Comparison to Industry Standards

• The company's LPT-CBD technology aims to provide a non-opioid alternative for chronic pain management, directly addressing the opioid crisis, which has strained healthcare systems with estimated costs reaching nearly $1.5 trillion annually in the U.S. (source: U.S. Senate Joint Economic Committee).
• The FDA's 505(b)(2) pathway, which Innocan is pursuing, is a streamlined regulatory route that utilizes existing data from approved products, such as Epidiolex (marketed by Jazz Pharmaceuticals), a CBD oral drug approved for epilepsy. This allows for a more efficient development process compared to a full NDA.
• Innocan's LPT-CBD demonstrated exceptionally high drug bioavailability (approaching 100%) in osteoarthritic dogs when compared to previously published pharmacokinetic data of CBD administered intravenously, contrasting with oral CBD administration which has a bioavailability range of only 6.5% to 20% (source: NIH).
• The company faces competition from major pharmaceutical companies like Jazz Pharmaceuticals (Epidiolex), AbbVie, Pfizer, Sanofi, and Bristol-Myers Squibb, which have significant financial resources, R&D capabilities, and established market presence in cannabinoid-based therapies and traditional pain management solutions (steroids, opioids, NSAIDs).
• New non-opioid pain medications, such as those approved by the FDA from Vertex Pharmaceuticals in January 2025, highlight the industry's shift towards safer alternatives, aligning with Innocan's strategic focus.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently subject to any material legal proceedings.

Related Party Transactions

• **Agreement with Tamar Innovest Limited:** On August 3, 2023, Tamar Innovest Limited, a company associated with director Ralph C.L Bossino and the largest shareholder, purchased 17,391 units in a private placement for $179,400. On March 7, 2025, Tamar Innovest Limited purchased a secured convertible debenture unit for $1,000,000, which includes a debenture convertible into common shares and warrants. A blocker provision prevents conversion/exercise if it would result in Tamar Innovest owning more than 19.99% of outstanding common shares.
• **Agreement with Brandzon Co. Ltd. B.I. Sky Global Ltd.:** On May 26, 2021, Innocan entered a founders agreement with Brandzon to establish B.I. Sky Global Ltd., a joint venture for non-CBD personal care and beauty products. Innocan holds 60%, and Brandzon holds 40%. Roni Kamhi, Innocan's COO, is the CEO and co-founding director of B.I. Sky. Innocan extended an owner's loan of approximately $3,000,000 to B.I. Sky, bearing interest and maturing in three years from issuance, with repayment extended until the earlier of February 15, 2026, or an exit event.
• **Loan to Iris Bincovich:** On July 1, 2020, a non-interest-bearing loan of $14,291 was extended to Iris Bincovich, the CEO, and was fully repaid by December 31, 2023.

Stakeholder Impact

• **Shareholders:** New investors will experience immediate dilution of $3.44 per common share. Existing shareholders' ownership interest will be diluted by the issuance of new shares. The IPO aims to provide capital for growth, potentially increasing long-term shareholder value, but the company's going concern status and history of losses pose risks.
• **Employees:** The company relies on retaining executive officers and attracting qualified personnel. Stock option plans and RSUs are used as incentives. Military service obligations in Israel could disrupt operations.
• **Patients (Human & Animal):** The development of LPT-CBD aims to provide safer, non-opioid alternatives for chronic pain management, potentially improving quality of life for millions.
• **Customers (Consumer Wellness):** The company's focus on innovative, high-performance self-care and beauty products, backed by research and efficacy testing, aims to build consumer trust and meet evolving needs.
• **Creditors:** The company's going concern warning and need for additional funding indicate potential risks for creditors if sufficient capital is not secured.

Next Steps

• Complete LPT-CBD scale-up activities (expected to commence approximately three months post-offering and take approximately one year).
• Conduct a Good Laboratory Practice (GLP)-compliant single-injection preclinical safety study for LPT-CBD (final reporting anticipated within 6-8 months).
• Submit an Investigational New Drug (IND) application to the FDA for the initial Phase 1a study, including clinical protocol and safety report.
• Commence Phase 1a first-in-human study 30 days post-IND submission, assuming no clinical hold is issued.
• Collect pharmacokinetic (PK) and exposure data of LPT-CBD during Phase 1a studies to form a scientific bridge to Epidiolex for a 505(b)(2) application (estimated to take 6-8 months, running parallel with Phase 1a).
• Begin Phase 1b studies immediately following approval of Phase 1a study results and completion of a repeated-dose GLP safety study.
• Submit an INAD application with the FDA-CVM during the second half of 2025 to commence testing LPT-CBD in the U.S. for animal health.
• Perform an efficacy pilot, full Chemistry, Manufacturing, and Controls (CMC) development, and scale-up for veterinary applications.
• Expand product portfolio with new developments and releases in the Consumer Wellness segment.
• Engage pharmaceutical companies and industry leaders in licensing discussions for LPT-CBD once key regulatory milestones are achieved for human and animal health applications.
• Continue to invest in product reach across digital commerce, online channels, and distribution partners for wellness products.
• Implement regulations for the Modernization of Cosmetic Regulation Act of 2022 (MoCRA) for cosmetic products.

Key Dates

Keywords

Innocan Pharma, LPT-CBD, Cannabidiol, Drug Delivery, Chronic Pain Management, Non-Opioid, Pharmaceuticals, Consumer Wellness, IPO, NYSE American, SEC F-1/A, Preclinical Development, FDA Approval, 505(b)(2) Pathway, Veterinary Medicine, Hemp-derived CBD, Biotechnology, Medical Research, Corporate Governance, Israel Operations, Capital Raise